Oncology
Sevabertinib Makes HER2 Testing Pivotal in NSCLC
The FDA’s accelerated approval covers previously treated adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine-kinase-domain mutations detected by an approved test.
Rayan Salih · October 23, 2026 · 6 min